|
1
|
Braun J, Hoang-Vu C, Dralle H and
Hüttelmaier S: Downregulation of microRNAs directs the EMT and
invasive potential of anaplastic thyroid carcinomas. Oncogene.
29:4237–4244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vriens MR, Weng J, Suh I, Huynh N,
Guerrero MA, Shen WT, Duh QY, Clark OH and Kebebew E: MicroRNA
expression profiling is a potential diagnostic tool for thyroid
cancer. Cancer. 118:3426–3432. 2012. View Article : Google Scholar
|
|
3
|
Hartmann C, Mueller W and von Deimling A:
Pathology and molecular genetics of oligodendroglial tumors. J Mol
Med (Berl). 82:638–655. 2004. View Article : Google Scholar
|
|
4
|
Geraldo MV, Fuziwara CS, Friguglieti CU,
Costa RB, Kulcsar MA, Yamashita AS and Kimura ET: MicroRNAs
miR-146-5p and let-7f as prognostic tools for aggressive papillary
thyroid carcinoma: A case report. Arq Bras Endocrinol Metabol.
56:552–557. 2012. View Article : Google Scholar
|
|
5
|
Lv M, Zhang X, Li M, Chen Q, Ye M, Liang
W, Ding L, Cai H, Fu D and Lv Z: miR-26a and its target CKS2
modulate cell growth and tumorigenesis of papillary thyroid
carcinoma. PLoS One. 8:e675912013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peng Y, Li C, Luo DC, Ding JW, Zhang W and
Pan G: Expression profile and clinical significance of microRNAs in
papillary thyroid carcinoma. Molecules. 19:11586–11599. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hunt JP, Buchmann LO, Wang L and Abraham
D: An analysis of factors predicting lateral cervical nodal
metastases in papillary carcinoma of the thyroid. Arch Otolaryngol
Head Neck Surg. 137:1141–1145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He H, Jazdzewski K, Li W, Liyanarachchi S,
Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al:
The role of microRNA genes in papillary thyroid carcinoma. Proc
Natl Acad Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pallante P, Visone R, Ferracin M, Ferraro
A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M,
Negrini M, et al: MicroRNA deregulation in human thyroid papillary
carcinomas. Endocr Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tetzlaff MT, Liu A, Xu X, Master SR,
Baldwin DA, Tobias JW, Livolsi VA and Baloch ZW: Differential
expression of miRNAs in papillary thyroid carcinoma compared to
multinodular goiter using formalin fixed paraffin embedded tissues.
Endocr Pathol. 18:163–173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weber F, Teresi RE, Broelsch CE, Frilling
A and Eng C: A limited set of human MicroRNA is deregulated in
follicular thyroid carcinoma. J Clin Endocrinol Metab.
91:3584–3591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Visone R, Pallante P, Vecchione A,
Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V,
Borbone E, et al: Specific microRNAs are downregulated in human
thyroid anaplastic carcinomas. Oncogene. 26:7590–7595. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JC, Gundara JS, Glover A, Serpell J
and Sidhu SB: MicroRNA expression profiles in the management of
papillary thyroid cancer. Oncologist. 19:1141–1147. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
96(Suppl): R40–R44. 2007.PubMed/NCBI
|
|
15
|
Li X, Abdel-Mageed AB, Mondal D and Kandil
E: MicroRNA expression profiles in differentiated thyroid cancer, a
review. Int J Clin Exp Med. 6:74–80. 2013.
|
|
16
|
Braun J and Hüttelmaier S: Pathogenic
mechanisms of deregulated microRNA expression in thyroid carcinomas
of follicular origin. Thyroid Res. 4(Suppl 1): S12011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
18
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ling H, Fabbri M and Calin GA: MicroRNAs
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sondermann A, Andreghetto FM, Moulatlet
AC, da Silva Victor E, de Castro MG, Nunes FD, Brandão LG and
Severino P: MiR-9 and miR-21 as prognostic biomarkers for
recurrence in papillary thyroid cancer. Clin Exp Metastasis.
32:521–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiong Y, Zhang L, Holloway AK, Wu X, Su L
and Kebebew E: MiR-886-3p regulates cell proliferation and
migration, and is dysregulated in familial non-medullary thyroid
cancer. PLoS One. 6:e247172011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen YT, Kitabayashi N, Zhou XK, Fahey TJ
III and Scognamiglio T: MicroRNA analysis as a potential diagnostic
tool for papillary thyroid carcinoma. Mod Pathol. 21:1139–1146.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee KM, Choi EJ and Kim IA: microRNA-7
increases radiosensitivity of human cancer cells with activated
EGFR-associated signaling. Radiother Oncol. 101:171–176. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W,
Wu Z, Chen T, Wu W, Lobie PE and Zhu T: MicroRNA-7 inhibits
epithelial-to-mesenchymal transition and metastasis of breast
cancer cells via targeting FAK expression. PLoS One. 7:e415232012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fang Y, Xue JL, Shen Q, Chen J and Tian L:
MicroRNA-7 inhibits tumor growth and metastasis by targeting the
phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.
Hepatology. 55:1852–1862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hao Z, Yang J, Wang C, Li Y, Zhang Y, Dong
X, Zhou L, Liu J, Zhang Y and Qian J: MicroRNA-7 inhibits
metastasis and invasion through targeting focal adhesion kinase in
cervical cancer. Int J Clin Exp Med. 8:480–487. 2015.PubMed/NCBI
|
|
27
|
Suto T, Yokobori T, Yajima R, Morita H,
Fujii T, Yamaguchi S, Altan B, Tsutsumi S, Asao T and Kuwano H:
MicroRNA-7 expression in colorectal cancer is associated with poor
prognosis and regulates cetuximab sensitivity via EGFR regulation.
Carcinogenesis. 36:338–345. 2015. View Article : Google Scholar
|
|
28
|
Shi Y, Luo X, Li P, Tan J, Wang X, Xiang T
and Ren G: miR-7-5p suppresses cell proliferation and induces
apoptosis of breast cancer cells mainly by targeting REGγ. Cancer
Lett. 358:27–36. 2015. View Article : Google Scholar
|
|
29
|
Zhang X, Hu S, Zhang X, Wang L, Zhang X,
Yan B, Zhao J, Yang A and Zhang R: MicroRNA-7 arrests cell cycle in
G1 phase by directly targeting CCNE1 in human hepatocellular
carcinoma cells. Biochem Biophys Res Commun. 443:1078–1084. 2014.
View Article : Google Scholar
|
|
30
|
Wang B, Sun F, Dong N, Sun Z, Diao Y,
Zheng C, Sun J, Yang Y and Jiang D: MicroRNA-7 directly targets
insulin-like growth factor 1 receptor to inhibit cellular growth
and glucose metabolism in gliomas. Diagn Pathol. 9:2112014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu Z, Jiang Z, Huang J, Huang S, Li Y, Yu
S, Yu S and Liu X: miR-7 inhibits glioblastoma growth by
simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK
pathways. Int J Oncol. 44:1571–1580. 2014.PubMed/NCBI
|
|
32
|
Lu ZJ, Liu SY, Yao YQ, Zhou YJ, Zhang S,
Dai L, Tian HW, Zhou Y, Deng HX, Yang JL and Luo F: The effect of
miR-7 on behavior and global protein expression in glioma cell
lines. Electrophoresis. 32:3612–3620. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu DG, Wang YY, Fan LG, Luo H, Han B, Sun
LH, Wang XF, Zhang JX, Cao L, Wang XR, et al: MicroRNA-7 regulates
glioblastoma cell invasion via targeting focal adhesion kinase
expression. Chin Med J (Engl). 124:2616–2621. 2011.
|
|
34
|
Kalinowski FC, Brown RA, Ganda C, Giles
KM, Epis MR, Horsham J and Leedman PJ: microRNA-7: A tumor
suppressor miRNA with therapeutic potential. Int J Biochem Cell
Biol. 54:312–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chou YT, Lin HH, Lien YC, Wang YH, Hong
CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, et al: EGFR promotes
lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc
pathway that targets the Ets2 transcriptional repressor ERF. Cancer
Res. 70:8822–8831. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y,
Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an
oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Manser E, Leung T, Salihuddin H, Zhao ZS
and Lim L: A brain serine/threonine protein kinase activated by
Cdc42 and Rac1. Nature. 367:40–46. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jaffer ZM and Chernoff J: p21-activated
kinases: Three more join the Pak. Int J Biochem Cell Biol.
34:713–717. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kumar R, Gururaj AE and Barnes CJ:
p21-activated kinases in cancer. Nat Rev Cancer. 6:459–471. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
King H, Nicholas NS and Wells CM: Role of
P-21-activated kinases in cancer progression. Int Rev Cell Mol
Biol. 309:347–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dart AE and Wells CM: P21-activated kinase
4-not just one of the PAK. Eur J Cell Biol. 92:129–138. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shrestha Y, Schafer EJ, Boehm JS, Thomas
SR, He F, Du J, Wang S, Barretina J, Weir BA, Zhao JJ, et al: PAK1
is a breast cancer oncogene that coordinately activates MAPK and
MET signaling. Oncogene. 31:3397–3408. 2012. View Article : Google Scholar :
|
|
43
|
Chow HY, Jubb AM, Koch JN, Jaffer ZM,
Stepanova D, Campbell DA, Duron SG, O'Farrell M, Cai KQ,
Klein-Szanto AJ, et al: p21-Activated kinase 1 is required for
efficient tumor formation and progression in a Ras-mediated skin
cancer model. Cancer Res. 72:5966–5975. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li X, Liu F and Li F: PAK as a therapeutic
target in gastric cancer. Expert Opin Ther Targets. 14:419–433.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cai XZ, Wang J, Li XD, Wang GL, Liu FN,
Cheng MS and Li F: Curcumin suppresses proliferation and invasion
in human gastric cancer cells by downregulation of PAK1 activity
and cyclin D1 expression. Cancer Biol Ther. 8:1360–1368. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Singhal R and Kandel ES: The response to
PAK1 inhibitor IPA3 distinguishes between cancer cells with
mutations in BRAF and Ras oncogenes. Oncotarget. 3:700–708. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
McCarty SK, Saji M, Zhang X, Jarjoura D,
Fusco A, Vasko VV and Ringel MD: Group I p21-activated kinases
regulate thyroid cancer cell migration and are overexpressed and
activated in thyroid cancer invasion. Endocr Relat Cancer.
17:989–999. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ma Y, McCarty SK, Kapuriya NP, Brendel VJ,
Wang C, Zhang X, Jarjoura D, Saji M, Chen CS and Ringel MD:
Development of p21 activated kinase-targeted multikinase inhibitors
that inhibit thyroid cancer cell migration. J Clin Endocrinol
Metab. 98:E1314–E1322. 2013. View Article : Google Scholar : PubMed/NCBI
|
